KalVista Pharmaceuticals, Inc.
File an IND for a Phase 2 clinical trial of KVD824
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- Q1 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“KVD824 is in development for prophylactic treatment of HAE with an expected IND filing for a Phase 2 clinical trial in the first quarter of 2021.”
What we found
Evidence strength A What the grades mean
The company confirmed it filed its first U.S. IND for KVD824 in early 2021, which aligns with the first quarter 2021 deadline.
-
A KalVista Pharmaceuticals, Inc. 10-K filed 2021-07-13
“To conduct our planned Phase 2 clinical trial in the US, we filed our first US IND for KVD824 in early 2021.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory filing
- Indicative materiality
- Medium rules
- Action
- File
- Deliverable
- IND filing for KVD824 Phase 2 trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you KalVista Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C348911-023623 · Corrections policy